Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Poliomyelitis

In brief

The purpose of this study is to evaluate the safety and tolerability of co-administration of nOPV1 + nOPV2 in infants, relative to those receiving monovalent nOPV vaccines alone and whether two and/or three doses of co-administered nOPV1 and nOPV2 are non-inferior to corresponding doses of nOPV1 alone and nOPV2 alone.

Key facts

Study ID

NCT06895486

Run by

PATH

People needed

675

Starts

2025-11-11

Expected to finish

2026-12-28

Last updated by the study team

2026-01-09

Who can join

Age: 0 and older, up to 0. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy male or female infant 16 weeks (+ 7 days) of age, at the time of first study vaccination. Healthy as defined by the absence of any clinically significant medical condition or congenital anomaly as determined by medical history, physical examination, and clinical assessment by the investigator.
• Parent(s) willing and able to provide written informed consent prior to performance of any study-specific procedure.
• Resides in study area and parent understands and is able and willing to adhere to all study visits and procedures (as evidenced by a signed informed consent form (ICF) and assessment by the investigator).
• Prior to study vaccination has received EPI vaccines as per the study EPI schedule and has received a single dose of IPV at 6 weeks (+7 days) of age.
• Prior to study vaccination has received no doses of OPV, based upon no evidence of such vaccination per available documentation.
• Parent agrees for participant to receive routine infant and childhood immunizations as per the approved protocol-adjusted schedule.

You may not qualify if…

• Presence of anyone under 10 years of age in the participant's household (living in the same house or apartment unit) who does not have complete age appropriate vaccination status (as per local guidelines) with respect to poliovirus vaccines at the time of study vaccine administration.
• Member of the participant's household (living in the same house or apartment unit) who has received OPV based on the vaccination records in the previous 3 months before study vaccine administration. Participants from household where a member received investigational nOPV3 vaccine will also be excluded from the study.
• Low birth weight (LBW), defined as a birth weight of less than 2500 g (up to and including 2499 g) at the time of birth.
• Premature birth (less than 37 weeks gestation).
• From multiple births (due to increased risk of OPV transmissions between siblings).
• Moderate or severe (grade ≥ 2) acute illness at the time of eligibility/first study vaccination - temporary exclusion. Note: Participants with mild (grade 1) acute illnesses may be considered eligible at the discretion of the investigator.
• Presence of fever on the day of randomization/first study vaccination (axillary temperature ≥37.5˚C) - temporary exclusion.
• Presence of abnormal vital signs (respiratory rate and/or heart rate) for age on the day of randomization/first study vaccination - temporary exclusion.
• A known allergy, hypersensitivity, or intolerance to any components of the study vaccines, including all macrolide and aminoglycoside antibiotics (e.g., erythromycin and kanamycin).
• Any reported known or suspected immunosuppressive or immunodeficiency condition (including HIV infection) in the participant or household member. Topical and inhaled steroids are permitted.
• Receipt of any immune-modifying or immunosuppressant drugs prior to the first study vaccine dose or planned use during the study of study participants or a household member. Topical and inhaled steroids are permitted.
• Any known or suspected bleeding disorder in the participant that would pose a risk to venipuncture or intramuscular injection.
• Presence of severe malnutrition (weight-for- length/height z-score <-3SD median [per WHO published child growth standards]) - temporary exclusion if marginal and subsequently gains sufficient weight to attain z-score ≥-3 SD.
• Receipt of any investigational product prior to the first administration of study vaccine, or planned use during the study period.
• Receipt of rotavirus vaccine within 2 weeks prior to first study vaccination.
• Prior receipt of an investigational product containing poliovirus vaccine.
• Receipt of transfusion of any blood product or immunoglobulins prior to the first administration of study vaccine or planned use during the study period.
• Parent or participant has any condition that in the opinion of the investigator would increase the participant's health risks in study participation or would increase the risk of not achieving the study's objectives (e.g., would compromise adherence to protocol requirements or interfere with planned safety and immunogenicity assessments).

Where it is running

• Cevaxin - 24 de Diciembre — Panama City, Panama (enrolling)
• Cevaxin - Ave. México — Panama City, Panama (enrolling)
• Cevaxin - Chorrera — Panama City, Panama (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.